The Menarini Group and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, have announced an exclusive worldwide license and collaboration agreement with Georgiamune for GIM-621. GIM-621 is a preclinical-stage first-in-class oral small molecule immunotherapy with potential application across multiple solid tumours. It is one… Read More
Gan & Lee Pharmaceuticals and Menarini have announced plans to collaborate on the registration and commercialisation of Gan & Lee’s glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide. The drug is under development for the treatment of adults with obesity or overweight, administered once every two weeks. … Read More
The UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the use of Nexpovio (selinexor), in combination with bortezomib and dexamethasone, as a treatment for eligible multiple myeloma patients who have received one or two prior treatments. The recommendation follows recent… Read More
The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer has been approved in the US. The Food and Drug Administration (FDA) has approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+,… Read More
